Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17396071 | 1.00 | ALDH1A1 (0.46) | ALDH1A1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL15367045 | 0.88 | ALDH1A1 (0.47) | ALDH1A1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL12066763 | 0.88 | ALDH1A1 (0.47) | ALDH1A1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL1914063 | 0.88 | ALDH1A1 (0.44) | ALDH1A1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL18815238 | 0.82 | OPRD1 (0.40) | — | |
| SCHEMBL18815239 | 0.82 | OPRD1 (0.40) | — | |
| SCHEMBL11982069 | 0.82 | OPRD1 (0.43) | ALDH1A1TSHRL3MBTL1PTGESNPSR1 | |
| SCHEMBL14479516 | 0.82 | OPRD1 (0.43) | ALDH1A1TSHRL3MBTL1PTGESNPSR1 | |
| SCHEMBL18291891 | 0.82 | ALDH1A1 (0.46) | ALDH1A1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL18845574 | 0.82 | OPRD1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868758-B2 | Betulinic proline imidazole derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2018-01-16 | — | — | US | disclosed |
| US-20170129917-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-05-11 | — | — | US | disclosed |
| WO-2016001820-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, PREP | ALDH1A1 4180/4885TSHR 4703/4885L3MBTL1 3063/4885 |
| US-20170129917-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, IMPA1 | ALDH1A1 4100/4885TSHR 4740/4885L3MBTL1 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.